Page 18 - Read Online

Page 14 of 14 Haydu et al. J Cancer Metastasis Treat 2021;7:36 https://dx.doi.org/10.20517/2394-4722.2021.39

48. Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-
MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978-88. DOI PubMed
49. Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood
2019;134:860-6. DOI PubMed PMC
50. Novo M, Ruff MW, Skrabek PJ, Lin Y. Axicabtagene ciloleucel chimeric antigen receptor T Cell therapy in lymphoma with secondary
central nervous system involvement. Mayo Clin Proc 2019;94:2361-4. DOI PubMed
51. Bennani NN, Maurer MJ, Nastoupil LJ, et al. Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS
involvement: results from the US lymphoma CAR T consortium. Blood 2019;134:763. DOI
52. Abbasi A, Peeke S, Shah N, et al. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic
remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol
2020;13:1. DOI PubMed PMC
53. Siddiqi T, Wang X, Palmer J, et al. CD19-targeting CAR-T cell therapy in CNS lymphoma. Blood 2019;134:4075. DOI
54. Jacobson CA, Westin JR, Miklos DB, et al. Abstract CT055: phase 1/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-
Cel) in combination with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma
(DLBCL). Cancer Res 2020;80:CT055. DOI
55. Jaeger U, Worel N, McGuirk JP, et al. Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab
in patients with relapsed/refractory diffuse large B-CELL lymphoma. Blood 2019;134:5325. DOI
56. Ruella M, Kenderian SS, Shestova O, et al. The Addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells
(CART19) improves responses against mantle cell lymphoma. Clin Cancer Res 2016;22:2684-96. DOI PubMed
57. Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Blood 2016;127:1117-27. DOI PubMed PMC
58. Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL
after ibrutinib failure. Blood 2020;135:1650-60. DOI PubMed PMC
59. Wierda WG, Dorritie KA, Munoz J, et al. Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination
with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Blood 2020;136:39-40.
60. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell
therapy of chronic lymphocytic leukemia. Nat Med 2018;24:563-71. DOI PubMed PMC
61. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR
T cells. Sci Transl Med 2017;9:eaaj2013. DOI PubMed
62. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med
2020;382:545-53. DOI PubMed PMC
63. Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted
CAR immunotherapy. Nat Med 2018;24:20-8. DOI PubMed PMC
64. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate
ovarian tumors in vivo. Oncoimmunology 2015;4:e994446. DOI PubMed PMC
65. Avanzi MP, Yeku O, Li X, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through
activation of the endogenous immune system. Cell Rep 2018;23:2130-41. DOI PubMed PMC
66. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-
mediated inhibition. J Clin Invest 2016;126:3130-44. DOI PubMed PMC
67. Ramos CA, Rouce R, Robertson CS, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B
cell non-Hodgkin's lymphomas. Mol Ther 2018;26:2727-37. DOI PubMed PMC
68. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Nature 2017;543:113-7. DOI PubMed PMC